Therapeutic Advances in Pediatric Multiple Sclerosis

Pediatric-onset multiple sclerosis (POMS) is a chronic, immune-mediated disorder that affects the central nervous system in children and adolescents. Approximately 3–10% of MS patients have an onset that occurs before the age of 18. The vast majority of pediatric MS cases are characterized by a rela...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Children (Basel) Ročník 12; číslo 3; s. 259
Hlavní autoři: Walsh, Rachel, Chitnis, Tanuja
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland MDPI AG 20.02.2025
MDPI
Témata:
B cells
Children
Clinical trials
Development and progression
Disease
disease-modifying therapy
Diseases
EDSS
Immunomodulators
Induction therapy
Interferon
Multiple sclerosis
Ofatumumab
Pathogenesis
Patients
pediatric multiple sclerosis
pediatric-onset multiple sclerosis (POMS)
Pediatrics
PIRA
RAW
Review
United States
Italy
Mississippi
RAW
pediatric multiple sclerosis
pediatric-onset multiple sclerosis (POMS)
PIRA
disease-modifying therapy
EDSS
ISSN:2227-9067, 2227-9067
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Pediatric-onset multiple sclerosis (POMS) is a chronic, immune-mediated disorder that affects the central nervous system in children and adolescents. Approximately 3–10% of MS patients have an onset that occurs before the age of 18. The vast majority of pediatric MS cases are characterized by a relapsing-remitting course with a high burden of disease activity. Pediatric MS patients were historically treated off-label with varying degrees of success. With the approval of many new therapies for adult-onset MS, alternative treatments in pediatric MS have rapidly started to emerge. In this narrative review, we will discuss therapeutic advancements in pediatric multiple sclerosis, including the seminal trials of PARADIGMS, which evaluated fingolimod use in pediatric MS patients, CONNECT (dimethyl fumarate), TERIKIDS (teriflunomide), OPERETTA I (ocrelizumab), and LEMKIDS (alemtuzumab). We will also review the safety and efficacy of different monoclonal antibodies that are commonly prescribed for multiple sclerosis. We will then examine induction versus escalation treatment strategies and conclude with discussions on treatment considerations in POMS patients.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2227-9067
2227-9067
DOI:10.3390/children12030259